



PRESS RELEASE  
28 May 2025 13:50:00 CEST

## TEQCool Expands Business Target Beyond Therapeutic Hypothermia into Multi-Billion-Dollar Brain Metabolism Reduction Markets

TEQCool AB today announced a strategic repositioning of its patented non-invasive, intranasal brain cooling system technology to address the vast global market for brain metabolism reduction, expanding beyond the therapeutic hypothermia market.

### Addressing a Critical, Under-Served Need

While dedicated standalone markets for targeted brain temperature reduction do not yet exist, the underlying demand spans multiple established segments, TEQCool is now targeting a spectrum of life-threatening neurological conditions—opening access to markets projected to exceed \$84 billion by 2030:

- **Traumatic Brain Injury (TBI):** \$13.7 billion
- **Subarachnoid Hemorrhage (SAH):** \$4.2 billion
- **Status Epilepticus (SE):** segment of the \$2.1 billion
- **Stroke (Ischemic & Hemorrhagic):** \$61.7 billion by
- **Neonatal Hypoxic-Ischemic Encephalopathy (HIE):** \$1.9 billion

Each of these multi-billion-dollar markets underscores the urgent need for superior neuroprotection—and positions TEQCool to capture significant share by integrating seamlessly into existing treatment protocols.

### Fueling Innovation with Clinical Collaboration

*“Built on decades of Lund University research and refined through pre-clinical and early clinical studies, TEQCool’s technology has garnered enthusiastic endorsement from the neuro-critical community. Our interviews with leading neurosurgeons, intensivists and neurocritical-care specialists, continues to point to one thing: there is no tool like TEQCool, they recognize that precisely lowering brain temperature and oxygen demand could be the game-changer in preventing secondary injury—yet until now, no technology has been capable of delivering rapid, targeted cooling without risking whole-body hypothermia or invasive procedures. It’s obvious to us that if they have a rapid, targeted, non-invasive brain cooling option like the TEQCool’s technology, they will use cooling more in reducing brain metabolism and preventing secondary injury.”* says the Anders Sjögren, CEO.

### A Proven, Patented Platform with Unmatched Precision

TEQCool’s system employs patented balloon catheters inserted into the nasal cavity and nasopharynx to harness the body’s natural heat-exchange pathways. With the potential to achieve targeted brain cooling of approximately 2 °C within one hour—without surgery or deep



**PRESS RELEASE**  
28 May 2025 13:50:00 CEST

sedation, this unique approach has the potential to minimize systemic complications and keep the patient fully accessible to clinicians throughout treatment.

#### **To Our Highly Esteemed Investors**

*"The journey ahead of us is definitely exciting and promising,"* says Vivien Ibironke Ibiyemi, COO of TEQCool. TEQCool invites current and prospective shareholders to join in this pivotal expansion. With regulatory pathways advancing and initial clinical data demonstrating both safety and efficacy, we are poised to accelerate product development and commercial rollout across major global markets.

#### **For further information regarding TEQCool, please contact:**

Anders Sjögren, CEO TEQCool AB, E-mail: [ir@teqcool.com](mailto:ir@teqcool.com)

#### **About Us**

TEQCool AB is a medical technology company in Lund, Sweden. TEQCool is developing a unique, patented solution for selective cooling of the brain in patients at risk of oxygen deprivation. The company is initially targeting patients with severe brain damage who suffer from neurological fever, but the need exists in many areas, such as heart attack, stroke, blood poisoning, COVID and other serious viral diseases, neonatal, suicide attempts, etc. The intended therapy is based on many years of research and development at Lund University, as well as preclinical and clinical studies.